Follow on Google News News By Tag * Cancer * Pancreatic * Pipeline * Therapeutic * Oncology * Clinical * Drug * Gemzar * Therapeutics * Globaldata * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | New Market Report: Pancreatic Cancer - Pipeline Assessment and Market Forecasts to 2017Fast Market Research recommends "Pancreatic Cancer - Pipeline Assessment and Market Forecasts to 2017" from GlobalData, now available
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts. GlobalData estimated the global pancreatic cancer therapeutics market, in 2009, at $781m indicating a cumulative annual growth rate (CAGR) of 9.9% between 2001 and 2009. The growth in the market can mainly attributed to the growth in the sales of the currently approved products. In addition, the successful launch of the biologic Tarceva into the pancreatic cancer market improved the market revenues and the drug, in combination with Gemzar (gemcitiabine) GlobalData analyzed that current competition in the pancreatic cancer therapeutics market is very strong. Gemzar dominated the pancreatic cancer therapeutics market in 2009. Patients who fail to elicit a therapeutic response to Gemzar are prescribed combinations (with Xeloda or biologics like erlotinib). Gemzar. The current market is further expected to witnesse a drop in revenues due to the patent expiry of Gemzar in the US. The pancreatic cancer pipeline is very strong. The pancreatic cancer developmental pipeline is strong with over 390 products in various phases of clinical development. Clinical development is more prominent in Phase II, which consists of 256 products, accounting for two third of the pipeline. Phase III consists of 29 products. The pipeline is dominated by combination therapies and most first-in-class molecules being studied are in combination with drugs already approved for pancreatic cancer. Scope The scope of the report includes: * Annualized global pancreatic cancer therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2017. * Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. * Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors, topoisomerase I inhibitors, tumor-targeted gene therapies and stem cell therapies. * Analysis of the current and future market competition in the global pancreatic cancer therapeutics. Key future market players covered are Pfizer, Novartis AG, NewLink Genetics, Wilex Inc. Amgen Inc, OncoTherapy Science, Inc. and KAEL-GemVax. * Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. * Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with pancreatic cancer therapeutics market. Reasons to buy The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to: * Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. * Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer therapeutics market. * Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pancreatic cancer therapeutics market in future. * Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. * Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. * Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. * What's the next big thing in the global pancreatic cancer therapeutics market landscape? - Identify, understand and capitalize. For more information or to purchase this report, go to: - http://www.fastmr.com/ About GlobalData GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number